Age related macular degeneration 10

disease
On this page

Also known as age related macular degeneration type 10ARMD10macular degeneration, age-related, 10macular Degeneration, age-related, type 10TLR4 age-related macular degeneration

Summary

Age related macular degeneration 10 (MONDO:0012674) is a disease and 1 clinical trial. Top therapeutic interventions include x-82. A subtype of age-related macular degeneration — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameage related macular degeneration 10
Mondo IDMONDO:0012674
MeSHC566935
OMIM611488
DOIDDOID:0110022
UMLSC1969108
MedGen409758
GARD0024878
Is cancer (heuristic)no

Also known as: age related macular degeneration type 10 · ARMD10 · macular degeneration, age-related, 10 · macular Degeneration, age-related, type 10 · TLR4 age-related macular degeneration

Disease family

This is a subtype of age-related macular degeneration. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationmacular degenerationdegeneration of macula and posterior poleage-related macular degenerationage related macular degeneration 10

Related subtypes (14): wet macular degeneration, age related macular degeneration 2, age related macular degeneration 1, macular degeneration, age-related, 3, age related macular degeneration 7, age related macular degeneration 4, age related macular degeneration 9, age related macular degeneration 11, age related macular degeneration 6, age related macular degeneration 8, age related macular degeneration 12, age related macular degeneration 14, macular dystrophy with central cone involvement, dry age related macular degeneration

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02348359PHASE2TERMINATEDX-82 to Treat Age-related Macular Degeneration

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
X-8221

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.